| Followers | 200 |
| Posts | 25574 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Saturday, December 04, 2021 4:20:52 AM
Instead they created a new contract with Congnate for the manufacture of DCVax Direct, thr links are in my earlier post with a complete explanation and quotes from the relevant contracts.
The reality of it, and I know this for certain as a knowledgeable person in this field, the original contract for DCVax-L continues to be the governing for the relationship with that matter; there is a new contract for DCVax Direct which the language in your quotes is not really about; and lastly, those contracts are about an ongoing relationship, but the DCVax-L contract says it is not terminated until the LATER of 7 years after it was signed or DCVax-L has been license for commercial sales for 5 years.
At that time, under this contract, the parties would still need to decide the necessary terms for commercial production.
Additionally the language in the annual financials is very clear on this point: while the company would prefer to do everything out of Sawston, this may not be possible for regulatory and practical reasons and they continue to have relationships with Cognate, and Fraunhofer if they need them.
The key takeaway is that despite the propagated view by certain interests on this board that Cognate is out of the picture and no contracts exist with them, this is very much not correct and is literally a lie.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
